Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors.

This review addresses key pharmacology and virology issues relevant in discovery and development of CCR5 antagonists as anti-HIV drugs, such as target validation, receptor internalization, allosterism, viral resistance and tropism. Recent progress in the discovery and development of CCR5 antagonists, SAR and clinical status are reviewed. Finally, modeling-based structure of CCR5 is discussed in the context of a small-molecule antagonism of the CCR5 receptor.

[1]  Steven M. Wolinsky,et al.  The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.

[2]  E. Whitehorn,et al.  Receptor-mediated Endocytosis of CC-chemokines* , 1997, The Journal of Biological Chemistry.

[3]  R. Doms,et al.  ChemR23, a putative chemoattractant receptor, is expressed in monocyte‐derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV‐1 strains , 1998, European journal of immunology.

[4]  M. Foda,et al.  Involvement of both the V2 and V3 Regions of the CCR5-Tropic Human Immunodeficiency Virus Type 1 Envelope in Reduced Sensitivity to Macrophage Inflammatory Protein 1α , 2000, Journal of Virology.

[5]  Ying Sun,et al.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.

[6]  M. Kavanaugh,et al.  A Critical Site in the Core of the CCR5 Chemokine Receptor Required for Binding and Infectivity of Human Immunodeficiency Virus Type 1* , 1999, The Journal of Biological Chemistry.

[7]  J. Moore,et al.  HIV-1 entry inhibitors: Evading the issue , 1999, Nature Medicine.

[8]  Martin S. Hirsch,et al.  Anti-Human Immunodeficiency Virus Interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with Other Antiretroviral Agents In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[9]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.

[10]  M. Maccoss,et al.  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. , 2001, Bioorganic & medicinal chemistry letters.

[11]  M. Oppermann,et al.  Differential Effects of CC Chemokines on CC Chemokine Receptor 5 (CCR5) Phosphorylation and Identification of Phosphorylation Sites on the CCR5 Carboxyl Terminus* , 1999, The Journal of Biological Chemistry.

[12]  J. Rossi,et al.  Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. , 2000, Antisense & nucleic acid drug development.

[13]  J. Sheridan,et al.  Requirement of MIP-1 alpha for an inflammatory response to viral infection. , 1995, Science.

[14]  D. Taub.  Chemokine-leukocyte interactions. The voodoo that they do so well. , 1996, Cytokine & growth factor reviews.

[15]  R. Hubbard,et al.  Combined biophysical and biochemical information confirms arrangement of transmembrane helices visible from the three-dimensional map of frog rhodopsin. , 1998, Journal of molecular biology.

[16]  M. Maccoss,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes. , 2001, Bioorganic & medicinal chemistry letters.

[17]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[18]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[19]  A. Lesk,et al.  Structural mechanisms for domain movements in proteins. , 1994, Biochemistry.

[20]  J. Hoxie,et al.  CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Caron,et al.  Constitutively active alpha-1b adrenergic receptor mutants display different phosphorylation and internalization features. , 1999, Molecular pharmacology.

[22]  P. Gray,et al.  Chemokine expression in murine experimental allergic encephalomyelitis , 1995, Journal of Neuroimmunology.

[23]  C. Broder,et al.  Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  O. Nishimura,et al.  Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. , 2000, Journal of medicinal chemistry.

[25]  D. Hazuda,et al.  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity. , 2001, Bioorganic & medicinal chemistry letters.

[26]  Kuan-Teh Jeang,et al.  Mechanism of Transdominant Inhibition of CCR5-mediated HIV-1 Infection by ccr5Δ32* , 1997, The Journal of Biological Chemistry.

[27]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[28]  T. Standiford,et al.  "The good, the bad, and the ugly." The role of chemokines in models of human disease. , 1996, Journal of immunology.

[29]  E. sanders-Bush,et al.  Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization. , 1995, Molecular pharmacology.

[30]  H. Schuitemaker,et al.  Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection , 1997, Annals of Internal Medicine.

[31]  A. Blauvelt,et al.  Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection , 1997, Nature Medicine.

[32]  P. Pitha,et al.  Binding of Human Immunodeficiency Virus Type 1 to CD4 and CXCR4 Receptors Differentially Regulates Expression of Inflammatory Genes and Activates the MEK/ERK Signaling Pathway , 1998, Journal of Virology.

[33]  J. Hoxie,et al.  Phorbol Esters and SDF-1 Induce Rapid Endocytosis and Down Modulation of the Chemokine Receptor CXCR4 , 1997, The Journal of cell biology.

[34]  A. Luster,et al.  Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.

[35]  H. Loh,et al.  Receptor density and recycling affect the rate of agonist-induced desensitization of mu-opioid receptor. , 2000, Molecular pharmacology.

[36]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[37]  E. De Clercq,et al.  The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. , 1999, The Journal of clinical investigation.

[38]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[39]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[40]  M. Mack,et al.  Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity , 1998, The Journal of experimental medicine.

[41]  G Vassart,et al.  Multiple Charged and Aromatic Residues in CCR5 Amino-terminal Domain Are Involved in High Affinity Binding of Both Chemokines and HIV-1 Env Protein* , 1999, The Journal of Biological Chemistry.

[42]  R. Doms,et al.  Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses , 1997, Journal of virology.

[43]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[44]  C. Cheng‐Mayer,et al.  Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation , 1990, Journal of virology.

[45]  S. O. Smith,et al.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  B. Cullen,et al.  Role of chemokine receptors in HIV-1 infection and pathogenesis. , 1999, Advances in virus research.

[47]  M. Bolognesi,et al.  Enhancement of the HIV‐1 inhibitory activity of RANTES by modification of the N‐terminal region: dissociation from CCR5 activation , 2000, European journal of immunology.

[48]  J. Goedert,et al.  Genetic acceleration of AIDS progression by a promoter variant of CCR5. , 1998, Science.

[49]  P. Harrigan,et al.  Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro , 1998, Journal of Virology.

[50]  Ying Sun,et al.  The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.

[51]  D. Ho,et al.  Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Christopher J. Evans,et al.  Morphine Activates Opioid Receptors without Causing Their Rapid Internalization* , 1996, The Journal of Biological Chemistry.

[53]  W. O'brien,et al.  HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain , 1990, Nature.

[54]  C. Cheng‐Mayer,et al.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp!20 gene , 1991, Nature.

[55]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[56]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[57]  D. Hazuda,et al.  Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection. , 2001, Bioorganic & medicinal chemistry letters.

[58]  A. Maynard,et al.  Naturally Occurring CCR5 Extracellular and Transmembrane Domain Variants Affect HIV-1 Co-receptor and Ligand Binding Function* , 1999, The Journal of Biological Chemistry.

[59]  M. Goldsmith,et al.  Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[60]  C. Rouzioux,et al.  CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French Pediatric HIV Infection Study Group. , 1998, JAMA.

[61]  B. Neustadt,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. , 2001, Journal of medicinal chemistry.

[62]  R. Doms,et al.  An Orphan Seven-Transmembrane Domain Receptor Expressed Widely in the Brain Functions as a Coreceptor for Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus , 1998, Journal of Virology.

[63]  C. Martínez-A,et al.  HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. Doms.  Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. , 2000, Virology.

[65]  Eric Hunter,et al.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.

[66]  Joseph Sodroski,et al.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.

[67]  Steven M. Wolinsky,et al.  Relative resistance to HIV–1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high–risk sexual exposures , 1996, Nature Medicine.

[68]  R. Ji,et al.  Building three-dimensional structures of HIV-1 coreceptor CCR5 and its interaction with antagonist TAK779 by comparative molecular modeling. , 2000, Acta pharmacologica Sinica.

[69]  H. Ullum,et al.  Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1beta are associated with a decreased risk of HIV disease progression. , 1998, The Journal of infectious diseases.

[70]  X F Huang,et al.  Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[71]  R. Doms,et al.  Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. , 1997, Virology.

[72]  J. Moore,et al.  Viral phenotype and CCR5 genotype , 1999, Nature Medicine.

[73]  R. Doms,et al.  Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1 , 1997, Journal of virology.

[74]  F. Sánchez‐Madrid,et al.  Similarities and Differences in RANTES- and (AOP)-RANTES–triggered Signals: Implications for Chemotaxis , 1999, The Journal of cell biology.

[75]  D. Weissman,et al.  Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Serena Xu,et al.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[77]  O. Nishimura,et al.  A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[78]  P. Luciw,et al.  Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection , 1997, Journal of virology.

[79]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[80]  E A Emini,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes. , 2001, Bioorganic & medicinal chemistry letters.

[81]  Proteins-Paradigms of complex systems , 1995, Experientia.

[82]  D. Hazuda,et al.  CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines. , 2002, Bioorganic & medicinal chemistry letters.

[83]  R. Doms,et al.  Chemokine Receptor Utilization by Human Immunodeficiency Virus Type 1 Isolates That Replicate in Microglia , 1998, Journal of Virology.

[84]  Marc Parmentier,et al.  A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.

[85]  Hiroaki Mitsuya,et al.  Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5* , 2001, The Journal of Biological Chemistry.

[86]  C. Martínez-A,et al.  The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[87]  M. Karplus,et al.  Molecular dynamics simulations in biology , 1990, Nature.

[88]  D. Littman,et al.  Expression cloning of new receptors used by simian and human immunodeficiency viruses , 1997, Nature.

[89]  Douglas Richman,et al.  Viral Dynamics of HIV: Implications for Drug Development and Therapeutic Strategies , 1996, Annals of Internal Medicine.

[90]  S. Spector,et al.  The CCR5Delta32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment. , 2000, The Journal of infectious diseases.

[91]  R. Doms,et al.  The CC Chemokine I-309 Inhibits CCR8-dependent Infection by Diverse HIV-1 Strains* , 1998, The Journal of Biological Chemistry.

[92]  D. Hazuda,et al.  Combinatorial synthesis of CCR5 antagonists. , 2001, Bioorganic & medicinal chemistry letters.

[93]  W. Blattner,et al.  Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[94]  J. Schlessinger,et al.  Signal Transduction Due to HIV-1 Envelope Interactions with Chemokine Receptors CXCR4 or CCR5 , 1997, The Journal of experimental medicine.

[95]  D. Hoover,et al.  The crystal structure of met-rantes: comparison with native rantes and aop-rantes , 2000, Protein & Peptide Letters.

[96]  K. Peden,et al.  STRL33, A Novel Chemokine Receptor–like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line–tropic HIV-1 , 1997, The Journal of experimental medicine.

[97]  L. Chieco‐Bianchi,et al.  Co-receptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission , 2000, AIDS.

[98]  M. Marsh,et al.  Role of CD4 endocytosis in human immunodeficiency virus infection , 1995, Journal of virology.

[99]  H. Frauenfelder,et al.  Conformational substates in proteins. , 1988, Annual review of biophysics and biophysical chemistry.

[100]  C. Mackay,et al.  Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding , 1997, The Journal of experimental medicine.

[101]  R. Weiss,et al.  CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. , 1997, Virology.

[102]  A. Nishiguchi,et al.  Convenient efficient synthesis of TAK-779, a nonpeptide CCR5 antagonist: development of preparation of various ammonium salts using trialkylphosphite and N-halogenosuccinimide , 2001 .

[103]  Nancy Sullivan,et al.  CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro , 1997, The Journal of experimental medicine.

[104]  X. Wang,et al.  Allosteric regulation of CCR5 by guanine nucleotides and HIV-1 envelope. , 2001, Biochemical and biophysical research communications.

[105]  D. Hazuda,et al.  Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection. , 2001, Bioorganic & medicinal chemistry letters.

[106]  B. Cullen,et al.  HIV‐1‐induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR‐5 co‐receptor , 1997, The EMBO journal.

[107]  Ying Sun,et al.  Two Orphan Seven-Transmembrane Segment Receptors Which Are Expressed in CD4-positive Cells Support Simian Immunodeficiency Virus Infection , 1997, The Journal of experimental medicine.

[108]  B. Dewald,et al.  Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines. , 1994, Advances in immunology.

[109]  M. Cybulsky,et al.  Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. , 1996, The Journal of clinical investigation.

[110]  B. Kieffer,et al.  μ and δ Opioid Receptors Are Differentially Desensitized by the Coexpression of β-Adrenergic Receptor Kinase 2 and β-Arrestin 2 in Xenopus Oocytes* , 1997, The Journal of Biological Chemistry.

[111]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[112]  John P. Moore,et al.  Will Multiple Coreceptors Need To Be Targeted by Inhibitors of Human Immunodeficiency Virus Type 1 Entry? , 1999, Journal of Virology.

[113]  E. De Clercq,et al.  T-Cell-Line-Tropic Human Immunodeficiency Virus Type 1 That Is Made Resistant to Stromal Cell-Derived Factor 1α Contains Mutations in the Envelope gp120 but Does Not Show a Switch in Coreceptor Use , 1998, Journal of Virology.

[114]  M. Goldsmith,et al.  Multiple Extracellular Elements of CCR5 and HIV-1 Entry: Dissociation from Response to Chemokines , 1996, Science.

[115]  Marc Parmentier,et al.  Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor Specificity , 1996, Cell.

[116]  John L. Johnson,et al.  Increased Replication of HIV‐1 at Sites of Mycobacterium tuberculosis Infection: Potential Mechanisms of Viral Activation , 2001, Journal of acquired immune deficiency syndromes.

[117]  A. Trkola,et al.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[118]  M. Baggiolini,et al.  HIV blocked by chemokine antagonist , 1996, Nature.

[119]  S. Mccombie,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element. , 2001, Bioorganic & medicinal chemistry letters.

[120]  C. Martínez-A,et al.  Distinct expression and function of the novel mouse chemokine monocyte chemotactic protein-5 in lung allergic inflammation , 1996, The Journal of experimental medicine.

[121]  A. Garzino-Demo,et al.  The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infection , 1996, Nature Medicine.

[122]  N. Bunnett,et al.  Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. , 1997, The Biochemical journal.

[123]  R. Collman,et al.  Determinants of Entry Cofactor Utilization and Tropism in a Dualtropic Human Immunodeficiency Virus Type 1 Primary Isolate , 1998, Journal of Virology.

[124]  A. Trkola,et al.  Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.

[125]  E A Emini,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes. , 2001, Bioorganic & medicinal chemistry letters.

[126]  M. Marsh,et al.  Chemokine receptors - the new frontier for AIDS research. , 1996, Chemistry & biology.

[127]  R. Doms,et al.  HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[128]  J. Sodroski,et al.  HIV-1 Entry and Macrophage Inflammatory Protein-1β-mediated Signaling Are Independent Functions of the Chemokine Receptor CCR5* , 1997, The Journal of Biological Chemistry.

[129]  D. Weissman,et al.  Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor , 1997, Nature.

[130]  T. Haltia,et al.  Forces and factors that contribute to the structural stability of membrane proteins. , 1995, Biochimica et biophysica acta.

[131]  R. Ganju,et al.  Beta-chemokine receptor CCR5 signals via the novel tyrosine kinase RAFTK. , 1998, Blood.

[132]  R. Pomerantz.  Primary HIV-1 resistance: a new phase in the epidemic? , 1999, JAMA.

[133]  W. Greenlee,et al.  Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. , 2001, Journal of medicinal chemistry.

[134]  J. Edwardson,et al.  Endocytosis and recycling of G protein-coupled receptors. , 1997, Trends in pharmacological sciences.

[135]  M. Lederman,et al.  Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. , 1999, JAMA.

[136]  B. Cullen,et al.  Molecular mechanism of desensitization of the chemokine receptor CCR‐5: receptor signaling and internalization are dissociable from its role as an HIV‐1 co‐receptor , 1997, The EMBO journal.

[137]  Pascal Poignard,et al.  Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants , 1999, Journal of Virology.

[138]  E A Emini,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. , 2001, Bioorganic & medicinal chemistry letters.

[139]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[140]  H. Guy,et al.  Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function* , 1999, The Journal of Biological Chemistry.

[141]  C. Kleeberger,et al.  CCR5 promoter polymorphism and HIV-1 disease progression , 1998, The Lancet.

[142]  R. Weiss,et al.  Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion , 1997, Journal of virology.

[143]  Jean Salamero,et al.  HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.

[144]  D. Kabat,et al.  Cooperation of Multiple CCR5 Coreceptors Is Required for Infections by Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.

[145]  P. Wolynes,et al.  The energy landscapes and motions of proteins. , 1991, Science.